English Spanish Chinese Russian German Japanese Portuguese Hindi Telugu Tamil

Journal international du développement et de la recherche sur les médicaments

  • ISSN: 0975-9344
  • Indice h du journal: 44
  • Note de citation du journal: 59.93
  • Facteur d’impact du journal: 48.80
Indexé dans
  • Genamics JournalSeek
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • CiteFactor
  • Scimago
  • Répertoire d'indexation des revues de recherche (DRJI)
  • OCLC - WorldCat
  • Publions
  • MIAR
  • Commission des bourses universitaires
  • Pub européen
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
  • ResearchGate
Voir plus
Partager cette page

Abstrait

Tobramycin (TOBI® or TOBI PODHALER®) in Ventilator Associated Pneumonia: An Overview

Dhilleswara Rao V

Despite the fact that Ventilator Associated Pneumonia (VAP) has a high death rate, it is not yet defined very well. Mortality in patients with lung injury on mechanical ventilation is estimated as 24% in patients 15-19 years and 60% in patients 85 years or older. Very few studies have reported the use of tobramycin (TOBI® or Tobi Podhaler®) in VAP management. However, the use of such antibiotics for treatment of VAP is equivocal and no clinical evidences reported. Tobi Podhaler® contains active substance of tobramycin, which is available as capsules (28 mg). Tobi Podhaler® can be used as a hand-held device which suppresses the chronic lung infections caused by P. aeruginosa in patients aged >6 years. The recommended dose is four capsules twice a day in adults and children older than 6 years of age. It can be also used to treat Cystic Fibrosis (CF). This review highlights the advantages of treatment with TOBI (Tobi Podhaler®) in VAP patients and also a note on inhaled antibiotics in management of chronic respiratory infections.